by Plus Therapeutics | Aug 1, 2025 | LM
Today, on World Lung Cancer Day, we pause to recognize the strength of patients and survivors and to reflect on the critical need for continued research and innovation in lung cancer care. This annual observance shines a spotlight on the millions of people affected by...
by Plus Therapeutics | Jul 29, 2025 | LM
Leptomeningeal metastases (LM) remain one of the most challenging complications in neuro-oncology. At Plus Therapeutics, we are committed to changing that. Our ongoing ReSPECT-LM dose-optimization trial is currently evaluating the optimal treatment regimen for...
by Plus Therapeutics | Jul 23, 2025 | LM
Plus Therapeutics is pleased to announce the receipt of a $1.6 million advance payment from the Cancer Prevention and Research Institute of Texas (CPRIT), the world’s second-largest public cancer research funding agency. This payment is part of the $17.6 million grant...
by Plus Therapeutics | Jul 15, 2025 | LM
Plus Therapeutics is pleased to announce its participation in the upcoming Society for Neuro-Oncology (SNO) / American Society of Clinical Oncology (ASCO) CNS Metastases Conference, taking place August 14–16, 2025, at the Baltimore Waterfront Marriott Hotel in...
by Plus Therapeutics | Jul 8, 2025 | LM
Plus Therapeutics is pleased to announce that the first patients have been treated in the ReSPECT-LM dose optimization clinical trial, evaluating REYOBIQ™ (rhenium Re 186 obisbemeda) for the treatment of leptomeningeal metastases (LM)—a devastating and often...
by Plus Therapeutics | Jun 30, 2025 | LM
Plus Therapeutics is pleased to announce the initiation of the ReSPECT-LM dose optimization clinical trial for REYOBIQ™ (rhenium Re 186 obisbemeda), a radiotherapeutic designed to target and treat leptomeningeal metastases (LM)—a devastating complication of metastatic...
Recent Comments